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Abstract 21 
Aims: A novel alginate oligomer (OligoG CF-5/20) has been shown to potentiate antifungal therapy 22 
against a range of fungal pathogens.  The current study assessed the effect of this oligomer on in vitro 23 
virulence factor expression and epithelial invasion by Candida species.  24 
Methods and Results:  Plate substrate assays and epithelial models were used to assess Candida 25 
albicans (CCUG 39343 and ATCC 90028) invasion, in conjunction with confocal laser-scanning 26 
microscopy and histochemistry.  Expression of candidal virulence factors was determined 27 
biochemically and by quantitative PCR (qPCR).  Changes in surface charge of C. albicans following 28 
OligoG treatment were analysed using electrophoretic light scattering.  OligoG induced marked 29 
alterations in hyphal formation in the substrate assays and reduced invasion in the epithelial model 30 
(p<0.001).  Significant dose-dependent inhibition of phospholipase activity in C. albicans was evident 31 
following OligoG treatment (p<0.05).  Whilst OligoG binding failed to affect alterations in surface-32 
charge (p>0.05), qPCR demonstrated a reduction in phospholipase-B (PLB2) and SAPs (SAP4 and 33 
SAP6) expression.   34 
Conclusion: OligoG CF-5/20 reduced in vitro virulence factor expression and invasion by C. albicans.  35 
Signiﬁcance and Impact of the Study:  These results, and the previously described potentiation of 36 
antifungal activity, define a potential therapeutic opportunity in the treatment of invasive candidal 37 
infections.  38 
 39 
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Introduction 46 
The incidence of human fungal infections has risen annually with increasing numbers of 47 
immunocompromised patients (Miceli et al. 2011), in-dwelling prosthetic devices (Chen et al. 2011; 48 
Silva et al. 2012), broad-spectrum antibiotic use and cytotoxic/immunosuppressive therapy.  Candida 49 
species (Pfaller and Diekema 2007) are responsible for >50% of systemic fungal infections (Lass-Floerl 50 
2009) and are the most frequently-reported human nosocomial fungal pathogens.  In health, Candida 51 
exist as harmless commensal organisms on the skin-surface, oral mucosa and gastrointestinal tract 52 
(Lass-Floerl 2009).  Candida are, however, opportunistic pathogens in both local- and systemic 53 
infection; the latter being associated with both significant mortality (estimated at 30%) (Lass-Floerl 54 
2009) and high treatment costs (Ramage et al. 2005; Leroy et al. 2009).  55 
Candida readily form biofilms on epithelial and material surfaces which exhibit resistance to 56 
antifungals including polyenes and azoles (Kuhn et al. 2002).  Once a candidal biofilm is formed in 57 
vivo, elimination generally demands removal of the substratum which supports the biofilm.  However, 58 
removal of medical devices is often impossible, due to the patient’s underlying medical condition and/or 59 
the anatomic location of the biofilm (Ramage et al. 2006).  Following adhesion and biofilm formation, 60 
the ability of Candida (especially Candida albicans) to undergo morphological alteration and secrete 61 
hydrolytic enzymes facilitates invasion and contributes to their pathogenicity (Mayer et al. 2013).  The 62 
invasion of host-tissue in the pathogenesis of candidal infection is a complex combination of physical, 63 
mechanical and enzymatic events, which are both host- and microorganism-dependent.  Whilst adhesion 64 
to host tissues and morphogenesis contributes to candidal virulence (Yang 2003), virulence factor 65 
production is also associated with Candida invasion (Shimizu et al. 1996).  66 
Intact human epithelium acts as a considerable physical and chemical barrier against Candida 67 
spp. infection.  Candida spp. possess several discrete mechanisms to increase their dermal 68 
pathogenicity, with the expression of surface proteins, e.g. adhesins and invasins facilitating attachment 69 
(Nobile et al. 2006), and biofilm formation supporting persistence (Finkel and Mitchell 2011).  70 
Moreover, yeast-to-hyphal transition facilitates enzymatically-induced tissue invasion (Mayer et al. 71 
2013), and thigmotropism (contact sensing) directs site-specific invasion (Kumamoto 2008).  Candida 72 
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species are highly metabolically adaptable, having the ability to adapt to changes in environmental pH 73 
and nutritional availability, as well as having a robust stress-response mechanism (Mayer et al. 2013).   74 
Secretion of hydrolases is important for the pathogenicity of C. albicans and is mediated by 75 
three main enzyme classes: secreted aspartyl proteinases (SAPs), phospholipases (PL) and lipases 76 
(Mayer et al. 2013).  Distinct SAPS genes are known to facilitate active penetration of the cross-linked 77 
epithelial barrier of the skin (Schaller et al. 2000).  Increased expression of PL has been associated with 78 
antifungal resistance (Ying and Chunyang 2012), whilst secretion of SAPs have been implicated in 79 
systemic infections (Sanglard et al. 1997).  80 
Previous studies demonstrated the ability of a low molecular weight alginate, OligoG CF-5/20 81 
(OligoG), to modify bacterial biofilm assembly and reduced resistance to antimicrobial therapy (Khan 82 
et al. 2012; Powell et al. 2013; Roberts et al. 2013; Powell et al. 2014).  More recently, the ability of 83 
OligoG to inhibit growth and biofilm formation of Candida and Aspergillus spp. has been demonstrated 84 
(Tøndervik et al. 2014).  These changes were associated with significantly increased sensitivity to 85 
antifungal agents and marked decreases in hyphal formation (Tøndervik et al. 2014).  The extent to 86 
which these changes modulate binding to-, and invasion of, mucosal surfaces by fungal pathogens 87 
remains unknown.   88 
Candidal adhesion and invasion was investigated using an in vitro organotypic keratinocyte 89 
model in the presence and absence of OligoG.  Substrate assays and real-time PCR were employed to 90 
investigate the mechanisms responsible for the observed changes. 91 
 92 
Materials and methods 93 
Strains and routine culture media 94 
C. albicans CCUG 39343 (clinical isolate) and C. albicans ATCC 90028 (reference strain for antifungal 95 
susceptibility testing) and C. glabrata ATCC 2001 (non-hyphal producing control) were used in this 96 
study.  Candida were grown at 37°C for 18 h on Sabouraud dextrose agar (SDA, Oxoid) or in liquid 97 
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culture using Sabouraud dextrose broth (SAB, Lab M).  The alginate oligomer, OligoG CF-5/20, was 98 
prepared as previously described (Khan et al. 2012). 99 
 100 
Growth curves  101 
C. albicans ATCC 90028 was grown overnight in Yeast Nitrogen Base (YNB; BD Diagnostics, 102 
Cowley, UK) medium supplemented with 0.5% (w/v) glucose at 37°C.  The culture was diluted to 5 x 103 
106 cells ml-1 and placed in 96-well microtiter plates ± 0.2, 2 and 6% OligoG (w/v) at 37°C for 24 h, 104 
with a YNB ± OligoG blank.  Optical density was measured at 600 nm (Fluostar Omega plate reader; 105 
BMG LABTECH).  106 
 107 
Hyphal invasion assay 108 
Yeast Peptone Dextrose (YPD) agar was prepared (Roberts and Fink 1994) ± 0.2%, 2% and 6% OligoG.  109 
Plates were dried (1 h) at room temperature prior to use.  Overnight cultures of C. albicans ATCC 110 
90028 were grown in YPD broth at 37°C whilst shaking.  Candida  (20 l ≃ 1x107 cells ml-1 in YPD 111 
medium) were deposited on to the YPD agar surface (n=3) and incubated for 72 h at 37°C, followed by 112 
72 h at room temperature.  Hyphal agar invasion was examined after rinsing the colonies from the agar 113 
surface with deionized water (Roberts and Fink 1994).  Assays were conducted in triplicate in three, 114 
independent, experiments.  Photographs employed the same focal length.  Agar samples were stained 115 
using hematoxylin and eosin (H&E) to study hyphal invasion of the epithelium.  Light microscopy 116 
images (x100 objective lens) of control and OligoG-treated samples were taken. 117 
 118 
Reconstituted human epithelium model 119 
Reconstituted human oral epithelium (RHE) tissue was obtained from SkinEthic Laboratories (Nice, 120 
France).  RHE tissues (n=5) were placed in 6-well tissue culture plates with 1 ml of SkinEthic 121 
maintenance medium ± 0.2% OligoG (w/v).  Candida albicans ATCC 90028, cultured on SDA at 37C 122 
for 24 h, was inoculated into YNB medium supplemented with 0.5% glucose (w/v) for 12 h at 37°C 123 
under gentle agitation.  The cell-suspension was centrifuged and washed (x3) with phosphate buffered 124 
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saline (PBS).  Following direct counting using a hemocytometer, 50 µl of 2 x 106 cells ml-1 was added 125 
to the surface of each RHE and incubated for 1, 3, 6 or 12 h at 37°C in a humidified atmosphere with 126 
5% CO2.  Non-infected controls were included in all experiments.  The RHE were then rinsed (x2) in 127 
PBS to remove planktonic cells and bisected.  Half was fixed in 10% (v/v) formalin prior to being 128 
embedded in paraffin wax, with the remainder used immediately for LIVE/DEAD® staining (Molecular 129 
Probes-Invitrogen, Paisley, UK). 130 
 131 
Confocal laser scanning LIVE/DEAD® staining of RHE 132 
RHE samples from each time-point were placed on microscope slides and 100 µl of LIVE/DEAD® stain 133 
(containing 25 µmol l-1 SYTO® 9 and 15 µmol l-1  propidium iodide) applied directly to the tissue, as 134 
previously described (Boros-Majewska et al. 2015).  Treated samples were incubated for 30 min at 135 
37˚C in the dark prior to transfer to clean glass slides.  RHE samples were covered with Vectashield® 136 
mounting medium and confocal laser scanning microscopy (CLSM) performed (n=3) using a Leica 137 
TCS SP2 AOBS spectral confocal microscope (Leica Microsystems GmbH, Wetzlar, Germany).  138 
 139 
Periodic Acid-Schiff staining 140 
RHE sections (5 µm) were stained using Periodic Acid-Schiff (PAS) stain to study hyphal invasion of 141 
the epithelium.  Light microscopic images (x100 objective lens) of control and 0.2%-treated OligoG 142 
samples (n=144) were taken (10 images/section), and the depth of invasion (>3 per image) was analysed 143 
by direct measurement, using ImageJ software. 144 
 145 
Phospholipase (PL) activity plate assay   146 
Candida albicans ATCC 90028 and C. albicans CCUG 39343 (with C. glabrata ATCC 2001 used as 147 
a negative control) were screened for extracellular PL activity after growth on egg-yolk agar 148 
(Samaranayake et al. 1984).  Experiments employed OligoG in the overnight culture medium (prior to 149 
inoculation of the egg-yolk agar) and OligoG incorporated into the egg yolk agar at 0.2, 2 and 6% (w/v) 150 
without CaCl2.  Static overnight cultures in SAB were diluted 100-fold into fresh SAB ± 0.2%, 2% and 151 
6% (w/v) OligoG for 18 h at 37°C.  A standard inoculum of the test Candida (5 μl ≃ 107 cfu ml-1) was 152 
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deposited onto the egg-yolk agar and dried at room temperature.  Plates were incubated at 37°C for 3-153 
7 days; the diameter of the precipitation zone around the colony was then measured (n=3) and PL 154 
activity (Pz value) expressed as the ratio of the colony diameter to the total diameter of the colony and 155 
precipitation zone (Price et al. 1982).  156 
 157 
Secreted aspartyl protease (SAP) activity plate assay 158 
Candida albicans ATCC 90028, C. albicans CCUG 39343, and C. glabrata ATCC 2001 were screened 159 
for SAP production after growth on modified YNB medium (de Menezes Thiele et al. 2008). Briefly, 160 
1.5% agar (Sigma; w/v) and 0.2% glucose (w/v) was autoclaved followed by the addition of filter 161 
sterilized 1.17% YNB without ammonium sulfate, 0.2% bovine serum albumin (Sigma; w/v) and 0.01% 162 
Vitox (Oxoid; v/v). The inoculum preparation and analysis was identical to that described in the PL 163 
activity assay. 164 
 165 
Hemolysis plate assay 166 
Sheep-blood SDA, supplemented with 3% glucose, was prepared ± 0.2%, 2% and 6% OligoG.  Static 167 
overnight cultures of C. albicans CCUG 39343, C. albicans ATCC 90028 and C. glabrata ATCC 2001 168 
were incubated at 37°C in SAB.  Cultures were diluted 100-fold into SAB ± 0.2, 2 and 6% OligoG and 169 
re-incubated for 18 h at 37°C.  The overnight culture was centrifuged at 2,000 g for 5 min and re-170 
suspended in water to 1 x 107 cells ml-1; a 5µl inoculum was placed on each plate (n=3).  Plates were 171 
incubated at 37°C (48 h) and hemolysis production calculated by dividing the diameter of the colony 172 
by the total colony diameter (including the translucent periphery), to determine the hemolytic index, Hi 173 
(Yigit et al. 2011; Deorukhkar et al. 2014).  Controls included Streptococcus pyogenes (clinical strain; 174 
beta hemolytic), S. pneumoniae (ATCC 49619; alpha hemolytic) and Staphylococcus epidermidis 175 
(ATCC 14990; negative control) grown in Mueller-Hinton broth. 176 
 177 
RNA extraction and Real-Time-PCR (qPCR) 178 
RNA was extracted from C. albicans ATCC 90028 cultured as described above.  Cultures were adjusted 179 
to 1.0 x 108 cells ml-1 in PBS and centrifuged (12000 g, 2 min) before being re-suspended in 0.5 ml 180 
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RNAlater® and stored at -20°C until required.  Cells were pelleted (12000 x g, 2 min) and re-suspended 181 
in lysis buffer (RLT buffer, QIAgen, Crawley, UK) containing 1% (v/v) beta-mercaptoethanol.  Cells 182 
were then lysed using a Mini-Bead-Beater-8 for a total of 4 min (at 2 min intervals with 1 min on ice).  183 
Resultant supernatants were transferred to fresh tubes, and the cell-debris pelleted by centrifugation.  184 
Total nucleic acid was extracted from the supernatant using 500 l phenol:chloroform:isoamyl alcohol 185 
(25:24:1) (Sigma-Aldrich, Pool, UK).  Total RNA was recovered from the aqueous layer after DNase I 186 
treatment using the RNeasy Mini Kit (QIAGEN).  Gel electrophoresis was used to check purity and 187 
integrity of the total RNA, and RNA concentration was measured spectrophotometrically (NanoVue, 188 
GE Healthcare, Little Chalfont, UK) and standardized to 300 ng ml-1.  Reverse transcription reactions 189 
for cDNA synthesis were performed using a total RNA template of (300 ng ml-1), 40 µmol of random 190 
nonamer primers (PrimerDesign Ltd) and molecular grade water in a final reaction volume of 10 μl.  191 
An annealing step of 5 min at 65°C was performed, samples were cooled on ice and added to the 192 
extension mix; 4 µl of 4 x NanoScript2 buffer, 1 µl dNTP mix (10 mM), NanoScript2 enzyme at 1.5 µl 193 
(Primer Design, Southampton, UK), and 2.5 µl of molecular grade water and a final volume of 20 µl 194 
was incubated at 25°C for 5 min and then at 42°C for 20 min.  195 
The primers used in the qPCR analysis were based on previous findings, and are shown in Table 196 
1.  Primer specificity was tested on extracted genomic DNA.  Regions amplified were secreted aspartyl 197 
proteinases SAP4, SAP5 and SAP6 and phospholipases PLB1 and PLB2, with ACT1 serving as a 198 
reference control for C. albicans.  PCR was performed in 96-well plates in an ABI 7000 instrument 199 
(Life Technologies).  Each 25 μl reaction contained 2 μl cDNA, 12.5 μl (x2) of SYBR-Green PCR 200 
master mix (PrecisionPlus Mastermix; Primer Design, Southampton, UK), 0.5 μl of each primer (10 201 
mM), made up to 25 μl with molecular grade water. The thermal cycle profile comprised of initial 202 
denaturation at 95°C for 2 min, 40 cycles of denaturation at 95°C for 15s, primer annealing at 58°C for 203 
15s, and primer extension at 72°C for 30s.  A final extension at 72°C for 2 min was performed, followed 204 
by a final cooling step at 4°C.  A dissociation stage at 60°C was used to generate a melting-curve for 205 
verification of the amplified product.  After qPCR, the threshold was adjusted according to the 206 
amplification curves of all evaluated genes.  Comparison between groups was based on the cycle 207 
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number at which both the target and reference genes reached threshold cycle (Ct) fluorescence.  208 
Analysis of relative gene expression was according to the ΔΔCT method (Bustin et al. 2009).  209 
 210 
Candida cell-surface charge analysis 211 
Zeta-potential analyses were performed using electrophoretic light scattering on C. albicans 39343 at 212 
pH 5, 7 and 9 and at a salt concentration of 0.01 mol l-1 NaCl.  C. albicans was grown overnight in SAB 213 
at 37°C, and diluted 100-fold in fresh SAB prior to culture at 37°C for 19 h at 80 rev min-1.  One ml of 214 
the culture was washed in distilled-water (5,500 x g; 3 min).  The pellet was re-suspended in 100 µl of 215 
0.01 mol l-1  NaCl (pH 5, 7 or 9) and 20 µl added to 1 ml of the buffer ± OligoG (10%) for 20 min; the 216 
sample was washed and centrifuged (2,500 x g; 6 min). A Zetasizer Nano ZS (Malvern Instruments) 217 
and disposable capillary cells (DTS1061 Malvern instruments) were employed and the resultant zeta 218 
potential calculated by applying Smoluchowski’s model (Wilson et al. 2001). 219 
 220 
Statistical analysis   221 
GraphPad Prism 3 was used to perform statistical analysis (GraphPad software Inc, California, USA).  222 
Measurements of invasion in the PAS-stained RHE images were analysed using a Mann-Whitney test.   223 
The data were analyzed by one-way ANOVA followed by a Dunnett Multiple Comparisons test (growth 224 
curve, SAP and PL plate assays) and Tukey Kramer multiple comparisons test (real-time PCR data). 225 
Data represents the mean in all figures (standard deviation; Fig. 1.-5, S1-S2 and standard error of mean 226 
in Fig. 6).  p<0.05 was considered significant.  227 
 228 
Results 229 
OligoG reduced candidal growth  230 
Growth curve studies showed that there was no change in the lag- or exponential-phases when C. 231 
albicans was grown in the presence of OligoG.  However, a decrease in optical density was evident at 232 
the late-exponential growth phase (>10 h) when samples were treated with ≥2% OligoG (Fig. 1a).  233 
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OligoG induced a significant dose-dependent reduction in candidal growth compared to the control (at 234 
18 h), which was maintained throughout stationary phase (Fig. 1b; p<0.05).  235 
 236 
OligoG reduced in vitro candidal hyphal production and invasion  237 
The hyphal invasion agar assay confirmed that treatment with OligoG (>0.2%) induced a marked dose-238 
dependent decrease in candidal invasion (Fig. 2). A visible reduction in the ability of C. albicans to 239 
penetrate the agar was seen at increasing OligoG concentrations.  H&E stained sections of the agar 240 
showed that considerable hyphal invasion was seen in the control samples, and interestingly this often 241 
led to a cluster of yeast cells penetrating through the agar along with the hyphae.  As the concentration 242 
of OligoG increased, less hyphae were visible, with reduced yeast cell clustering within the agar, 243 
particularly at OligoG concentrations ≥2%. Alternatively, hyphal cells may have reverted to yeast cells. 244 
Longitudinal CLSM studies of the RHE tissues showed candidal hyphal formation did not occur 245 
before 6 h (Fig. 3). However, in contrast to the control in which a vital epithelial layer was evident 246 
(depicted by viable green cells), hyphal formation was clearly evident at 6 h on the surface of the 247 
inoculated epithelial cells.  Moreover, at 12 h, there was an unmistakable further increase in hyphal 248 
formation, in conjunction with greater epithelial cell death (red cells).  This 12 h time point was 249 
therefore chosen as optimal for testing the RHE tissues with OligoG.   250 
Fig. 4 shows OligoG-treated RHE sections.  An intact epithelium composed of viable (green) 251 
keratinocytes in the controls (Fig. 4a), contrasted with increasing numbers of non-viable (red) 252 
keratinocytes and abundant hyphal formation in the infected RHE tissues, with a striking decrease in 253 
hyphal formation observed in the 0.2% OligoG-treated samples. No change in the ratio of live to dead 254 
cells was evident.  255 
Quantification of hyphal invasion was conducted using PAS-stained RHE cross-sectional 256 
images (Fig. 4b).  PAS images demonstrated intact stratified keratinocytes in the uninfected control.  257 
However, in the infected control, the stratified layers were clearly infiltrated with hyphae penetrating 258 
at least half way through the keratinocyte layers.  Quantification of hyphal invasion of the epithelial 259 
surface in the RHE model showed a statistically significant reduction in the depth of hyphal invasion 260 
observed in the 0.2% OligoG-treated RHE tissues (p<0.05; n=144 measurements of 10 images/section 261 
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with >3 measurements of depth of invasion/image) compared to the untreated control, with the hyphae 262 
seen predominantly on the tissue surface rather than invading the underlying keratinocytes.   263 
 264 
Production of the virulence factor phospholipase was reduced in the presence of OligoG 265 
Standard egg-yolk plates showed that phospholipase (PL) production by C. albicans ATCC 90028 cells 266 
pre-treated with OligoG  was significantly decreased, but only at the 5 day time point using 6% OligoG 267 
(Fig. 5; p<0.05).  Slight strain variations were evident, with no significance seen following OligoG pre-268 
treatment with strain CCUG39343.  However, incorporating OligoG into the egg-yolk plates produced 269 
a pronounced dose-dependent effect, with significantly decreased production of PL evident at days 3, 5 270 
and 7 (at ≥2% OligoG; p<0.05; Fig. 5) for both strains tested. 271 
Analysis of secreted aspartyl protease (SAPs) production showed that treatment of Candida 272 
with OligoG failed to induce significant differences in hemolytic activity, in either pre-treatment 273 
(p>0.05; Fig. S1a) or following incorporation of OligoG into the agar (p>0.05; Fig. S1b).  Unusually, 274 
the two C. albicans strains tested (ATCC 90028 and CCUG 39343) produced no SAPs in the plate 275 
assays, even in untreated controls after 7 day incubations, suggesting that the assay was not sufficiently 276 
sensitive.   277 
 278 
OligoG reduced expression of key phospholipase and secreted aspartyl proteinases   279 
Quantitative RT-PCR demonstrated OligoG induced a decrease in key phospholipase and secreted 280 
aspartyl proteinase production at concentrations ≥0.2%.  However, the data only reached statistical 281 
significance (p<0.05) for PLB2, SAP4 and SAP6 expression at 6% OligoG (Fig. 6). A dose-dependent 282 
decrease in SAP5 was also evident at 6% OligoG, however this did not reach statistical significance.  283 
 284 
OligoG did not alter the surface charge of the candidal cell wall 285 
Zeta-potential measurements demonstrated that the surface charge of Candida was increased following 286 
OligoG treatment, at pH 5 and 7 (not pH 9).  Following thorough washing, these changes were not 287 
significantly different from the control in any of these test conditions (Fig. S2).  288 
 289 
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Discussion 290 
This study demonstrated the effect of OligoG on the important human fungal pathogen C. albicans and 291 
showed the ability of this polymer therapy to modify virulence factor production and invasion of C. 292 
albicans in vitro.  Numerous in vivo, ex vivo and in vitro models of candidal biofilm formation and 293 
invasion have been developed.  Whilst no single in vitro model of Candida infection exists, numerous 294 
studies have employed this RHE model (de Fraissinette et al. 1999) which, although lacking any 295 
immunological component, has been extensively used to study Candida/keratinocyte 296 
interactions/invasion at the gene, protein and cellular level (Schaller et al. 2001; Schaller et al. 2002; 297 
Bartie et al. 2004; Jayatilake et al. 2005; Malic et al. 2007).  Although authors have criticized the model 298 
(Murdoch et al. 2005; Colley et al. 2011; Yadev et al. 2011) it is still useful as it allows the early events 299 
of fungal pathogenesis i.e. adhesion to the keratinocyte surface and initial invasion of the insoluble 300 
keratinocyte barrier of cross-linked proteins and lipids (Schaller et al. 2006) to be studied.  Researchers 301 
have also shown how strain-dependent invasiveness in the RHE may reflect pathogenicity in vivo (Malic 302 
et al. 2007).  It should also be borne in mind that in the early stages of pathogenesis, keratinocytes (via 303 
this physical barrier and their expression of cytokines and Toll-like receptors) represent an important 304 
element of the dermal innate immune response to fungal and many other pathogens (Mogensen 2009). 305 
Imaging revealed that no candidal hyphal infiltration was evident at <6 h.  Beyond 6 h however, 306 
adherence and hyphal formation were clearly evident.  At 12 h, LIVE/DEAD® staining demonstrated 307 
markedly decreased hyphal formation on the surface of the OligoG-treated RHE models, with few actual 308 
hyphae visible in contrast to the abundant hyphae present in the untreated control.  Whilst these results 309 
may appear to contrast with the growth inhibition described in previous studies, these were not however, 310 
apparent at early time points <12 h; the previously-described differences being evident only at 48 h 311 
(Tøndervik et al. 2014).  312 
Whilst attachment, proliferation and biofilm assembly are important in colonization of the 313 
epithelial surface, invasion is a key pathogenic phenotype in candidal pathogenesis (Bartie et al. 2004; 314 
Mayer et al. 2013).  Invasion studies here employed cross-sectional imaging of RHE as previously 315 
utilized in virulence studies of clinical Candida isolates (Malic et al. 2007; Boros-Majewska et al. 316 
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2014), which revealed that OligoG was not fungicidal (as ascertained by the absence of red-stained, 317 
non-vital cells), differential quantification of samples, as previously described by Boros-Majewska et 318 
al. (2014), could not be employed.  Analysis of invasion in the RHE and agar model systems revealed 319 
that whilst no differences in fungal viability were evident, OligoG treatment induced markedly reduced 320 
invasion in both model systems, with a dose-dependent decrease in hyphal formation being evident in 321 
the agar model.  Interestingly at high concentrations of OligoG (>6%) in the agar model, addition of the 322 
alginate oligomers reduced the structural integrity of the agar. The decreased invasion, therefore, did 323 
not reflect the OligoG induced alteration in physical density of the media.  The findings in the RHE 324 
model were in line with the reduced Candida growth demonstrated in the presence of OligoG.  It should 325 
be noted that the use of higher concentrations of OligoG (>2%) was not possible in this system as higher 326 
concentrations impaired both direct visualization and the cellular viability of the epithelial component 327 
of the superficial keratinocyte layer, in this (avascular) air-liquid interface model.  This effect on 328 
keratinocyte viability is a particular feature of this model and has not been observed in the extensive 329 
pre-clinical (in vitro), animal, and human clinical testing of chronically-inhaled OligoG prior to EMA 330 
and FDA approval (Pritchard et al. 2016). 331 
Dermal invasion by Candida is facilitated by production of a heterogeneous group of 332 
hydrolytic enzymes (Schaller et al. 2005).  SAPs are believed to mediate Candida invasion of epithelial 333 
cells, with SAP5 in particular, also strongly associated with proteolytic degradation of E-cadherin found 334 
in the intracellular junctions of keratinocytes (Villar et al. 2007).  Interestingly, as keratinocyte damage 335 
is not prevented by pepstatin A (which partially inhibits invasion), other mechanisms are, therefore, 336 
clearly important (Naglik et al. 2008).  SAPs 1-3 have been shown to have a direct role in the tissue 337 
damage of superficial infection whilst SAPs 4-6 are important for invasion and interaction with 338 
components of cellular defense (Schaller et al. 2001) and yeast to hypha transition (Naglik et al. 2003).  339 
A reduction in SAP4-6 in the presence of OligoG (being significant for SAP 4 and 6) could explain the 340 
corresponding decrease in hyphal formation and invasion.  However, the pathogenicity of SAPs remains 341 
contentious (Correia et al. 2010) with poor correlation found between individual SAP gene-expression 342 
and epithelial damage (Naglik et al. 2008).  SAP expression is also dependent on environmental pH 343 
(Staib et al. 2000), therefore, it is unsurprising that SAP production in C. albicans was not detected 344 
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phenotypically in this study.  The marked reductions in hyphal formation, which were induced by 345 
OligoG, were reflected in alterations in the gene expression of PLB2, SAP4 and SAP6, evident by qPCR 346 
analysis.  The lower expression of PLs and SAPs in the RHE model system may reflect their decreased 347 
expression in established laboratory isolates, and the reduced sensitivity of the plate-based assay in 348 
comparison to the qPCR (Boriollo et al. 2009). 349 
The effects of OligoG on hyphal formation and fungal invasion in the RHE model reflected its 350 
previously reported reduction of germ-tube formation in vitro (Tøndervik et al. 2014).  In vivo, invasion 351 
is not only mediated by hydrolytic enzymes, but may be potentiated by synergistic interactions with 352 
other bacterial species on the skin or mucosal surfaces e.g. Staphylococcus (Zago et al. 2015) and 353 
Streptococcus spp. (Bamford et al. 2009).  SAPs 4-6 were investigated due to their involvement in 354 
systemic infections (Malic et al. 2007).  SAP 4-6 are hyphal-specific; their expression being associated 355 
with invasive candidal strains.  It has recently been suggested that the importance of SAPs may be an 356 
over-stated epiphenomenon in ex-vivo systems, reflecting experimental conditions, rather than 357 
pathological invasion in vivo (Naglik et al. 2008).  Both SAPs 1-3 and SAPs 4-6 subfamilies were 358 
reported to be lower when analysed using qPCR in the RHE model, indicating that SAP production 359 
needs to be further analysed in vivo (Naglik et al. 2008).   360 
C. albicans is known to possess up to five extracellular phospholipases (PLB1-5) which may 361 
also play a role in virulence, possibly via disruption of the host membrane (Mayer et al 2013).  PL 362 
activity represents an important virulence factor in not only Candida, but also in a range of other fungi 363 
including Aspergillus (Alp and Arikan 2008), Cryptococcus (Ganendren et al. 2006) and bacteria such 364 
as Clostridium perfringens and Pseudomonas aeruginosa (Ghannoum 2000).  Candidal PLs are a 365 
heterogeneous group of important enzymes associated with invasion (Ghannoum 2000) and expression 366 
is localized to the peripheries of the hyphal tips and initial sites of bud- formation (Jayatilake et al. 367 
2005) (where they act as a mechanical anchor for yeast survival on the keratinocyte surface).  PL 368 
expression is reduced in non-hyphal forming species e.g. C. glabrata (Kantarcioglu and Yucel 2002) 369 
and are believed to modify host transduction pathways, perturb cell signaling (Oishi et al. 1988) and 370 
local immune responses (Soares et al. 2010).  Whilst PL expression has however previously been shown 371 
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not to correlate with RHE invasion in this model (Malic et al. 2007) it was interesting that the reduced 372 
hyphal formation and invasion induced by OligoG was associated with a significant decrease in Plb2.   373 
Studies of the interaction of OligoG with the Candida cell wall were deemed important as 374 
alterations in pseudomonal bacterial (and biofilm) behavior had previously been shown related to 375 
bacterial cell-surface binding and modification of cell-surface charge by long-range forces (which 376 
determine pathogen/host cell interactions) (Powell et al. 2014).  Interestingly, whilst ELS experiments 377 
with P. aeruginosa showed how alginate oligomers bound tightly to the bacterial cell surface and resist 378 
hydrodynamic shear, in Candida no such changes were apparent.  Treated candidal specimens also 379 
failed to demonstrate the “clumping”/aggregation previously observed in P. aeruginosa biofilms.  These 380 
findings reflect the contrasting nature of the yeast cell wall (composed of glucan, chitin and 381 
mannoproteins), with that of the lipid-rich pseudomonal outer membrane incorporating both 382 
peptidoglycan and lipopolysaccharide (Hawrani et al. 2010).  383 
In conclusion, these studies have demonstrated the ability of the alginate oligosaccharide 384 
OligoG CF-5/20, to modify virulence factor expression in Candida and inhibit hyphal formation and 385 
invasion.  The observed reduction in hyphal infiltration reflected reductions in hydrolytic enzyme 386 
production.  These findings demonstrate direct and indirect mechanisms by which OligoG may 387 
influence candidal invasion and be of potential utility in the management of fungal pathogens in human 388 
disease. 389 
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Table 1 Primers used for quantitative PCR. 589 
Target 
gene 
Additional 
information 
Forward primer (5' - 3') Reverse primer (5' - 3') Reference 
SAP4 Secreted aspartyl 
proteinase 
AATGATGTGGGCAAAGAGG ACACCACCAATACCAACGGT (Monod et al. 1994; Monod et 
al. 1998) 
SAP5 Secreted aspartyl 
proteinase 
ATTAATTGATGCGGCTCCAG ACACCACCAATACCAACGGT (Monod et al. 1994; Monod et 
al. 1998) 
SAP6 Secreted aspartyl 
proteinase 
TCCAAACCAACGAAGCTACC GCAGGAACGGAGATCTTGAG (Monod et al. 1994; Monod et 
al. 1998) 
PLB1 Phospholipase B CAACGAAGCGGTGTTGTCTA  TTGCTGCCAGAACTTTTGAA  (Sugiyama et al. 1999; 
Niewerth and Korting 2001) 
PLB2 Phospholipase B GGCCAGATGGATCAGCTTTA AAGTTCTGGGCATCACATCC (Sugiyama et al. 1999; 
Niewerth and Korting 2001) 
ACT1 C. albicans actin 
reference gene 
TGCTGAACGTATGCAAAAGG TGAACAATGGATGGACCAGA (Cavalcanti et al. 2015) 
 590 
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Figure legends 591 
Figure 1 Growth of C. albicans in the presence of OligoG. Growth curves of Candida albicans ATCC 592 
90028 (n=3) ± OligoG at 0% (○), 0.2% (□), 2% (●), 6% (■) over 24 h grown in SAB (a) Representative 593 
growth curves. (b) Mean optical density at 18 h time point (n=3; *p<0.05).  594 
 595 
Figure 2 Agar hyphal invasion model of C. albicans in the presence of OligoG. Yeast Peptone Dextrose 596 
agar plate assay ± OligoG (0.2%, 2% and 6%) showing hyphal invasion with corresponding light 597 
microscopy H&E stained images of cross-sectional agar slices (x20). 598 
 599 
Figure 3 Epithelial attachment of Candida in the RHE model. Time dependent invasion model showing 600 
LIVE/DEAD® CLSM images of RHE samples infected with C. albicans ATCC 90028 (2 x 106 cfu ml-601 
1) for 1, 3, 6 and 12 h, scale bar 40 µm. 602 
 603 
Figure 4 Imaging and quantification of OligoG treated C. albicans hyphal invasion in RHE. CLSM 604 
images of RHE samples infected with C. albicans ATCC 90028 for 12 h. (a) LIVE/DEAD® staining, 605 
scale bar 40µm; (b) Periodic acid–Schiff staining of fixed RHE samples (blue) infected with C. albicans 606 
ATCC 90028 (purple) and boxplot of hyphal invasion measurements (n=64; *p< 0.05). 607 
 608 
Figure 5 Phospholipase production of C. albicans in the presence of OligoG. C. albicans ATCC 90028 609 
and CCUG 39343 phospholipase plate assay ± OligoG in the overnight broth or agar (0.2%, 2% and 610 
6%) for 3 days (white), 5 days (grey) and 7 days (black) showing actual Pz values (*p< 0.05; n=3).  Pz 611 
of 1.0 = no phospholipase activity. 612 
 613 
Figure 6 Molecular quantification of hydrolytic enzyme production of C. albicans in the presence of 614 
OligoG. Relative gene expression of phospholipase B (PLB1, PLB2) and secreted aspartyl proteinases 615 
(SAPs 4, 5 and 6) following C. albicans ATCC 90028 treatment with OligoG (n=3; *p<0.05).  616 
 617 
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Supporting information 618 
Figure S1 C. albicans ATCC 90028 hemolysis agar plate assay ± OligoG 0.2%, 2% and 6% (a) in broth 619 
or (b) in agar.  620 
Figure S2  Mean Zeta Potential (mV) values for C. albicans CCUG 39343; untreated Candida (pre-621 
wash), treated Candida with 10% OligoG (pre-wash), untreated Candida (post-wash) and treated 622 
Candida with 10% OligoG (post-wash) at 0.01 mol l-1  NaCl, pH 5, 7 and 9. (^ false positive result). 623 
 624 
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